DE69732966D1 - Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf) - Google Patents

Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)

Info

Publication number
DE69732966D1
DE69732966D1 DE69732966T DE69732966T DE69732966D1 DE 69732966 D1 DE69732966 D1 DE 69732966D1 DE 69732966 T DE69732966 T DE 69732966T DE 69732966 T DE69732966 T DE 69732966T DE 69732966 D1 DE69732966 D1 DE 69732966D1
Authority
DE
Germany
Prior art keywords
nekrosis
indazone
pde
phosphodiesterase
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69732966T
Other languages
English (en)
Other versions
DE69732966T2 (de
Inventor
Anthony Marfat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69732966D1 publication Critical patent/DE69732966D1/de
Publication of DE69732966T2 publication Critical patent/DE69732966T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69732966T 1996-05-03 1997-04-01 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf) Expired - Fee Related DE69732966T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
US16861P 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
DE69732966D1 true DE69732966D1 (de) 2005-05-12
DE69732966T2 DE69732966T2 (de) 2005-09-08

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69732966T Expired - Fee Related DE69732966T2 (de) 1996-05-03 1997-04-01 Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)

Country Status (42)

Country Link
US (2) US6211222B1 (de)
EP (1) EP0912521B1 (de)
JP (1) JP3148254B2 (de)
KR (1) KR100339935B1 (de)
CN (2) CN1112359C (de)
AP (4) AP1147A (de)
AR (1) AR006906A1 (de)
AT (1) ATE292626T1 (de)
AU (1) AU725576B2 (de)
BG (1) BG64211B1 (de)
BR (1) BR9709051A (de)
CA (2) CA2252982C (de)
CO (1) CO4650038A1 (de)
CZ (1) CZ292825B6 (de)
DE (1) DE69732966T2 (de)
DZ (1) DZ2217A1 (de)
EA (1) EA002272B1 (de)
ES (1) ES2238079T3 (de)
GT (1) GT199700043A (de)
HK (1) HK1019443A1 (de)
HN (1) HN1997000046A (de)
HR (1) HRP970227B1 (de)
HU (1) HUP9902459A3 (de)
ID (1) ID16856A (de)
IL (2) IL152083A0 (de)
IS (1) IS4871A (de)
MA (1) MA24158A1 (de)
MY (1) MY132499A (de)
NO (1) NO312959B1 (de)
NZ (1) NZ332240A (de)
OA (1) OA10904A (de)
PE (1) PE64598A1 (de)
PL (1) PL329836A1 (de)
SK (1) SK148298A3 (de)
TN (1) TNSN97070A1 (de)
TR (1) TR199802202T2 (de)
TW (1) TW449585B (de)
UA (1) UA65536C2 (de)
UY (1) UY24532A1 (de)
WO (1) WO1997042174A1 (de)
YU (1) YU16397A (de)
ZA (1) ZA973804B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0983249B1 (de) * 1997-05-08 2002-03-13 Pfizer Products Inc. Verfahren und zwischenprodukte zur herstellung substituierter indazolderivate
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
TR200001234T2 (tr) * 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
YU25400A (sh) * 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
IL162506A0 (en) 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8277809B2 (en) * 2006-04-21 2012-10-02 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (de) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU217661B (hu) * 1992-03-09 2000-03-28 Zeneca Ltd. Aril-indazol-származékok, eljárás az előállításukra és herbicidként történő alkalmazásuk
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them
WO1996012770A1 (en) * 1994-10-21 1996-05-02 Elisha Technologies Co. L.L.C. Corrosion preventing buffer system for metal products
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
EP0983249B1 (de) * 1997-05-08 2002-03-13 Pfizer Products Inc. Verfahren und zwischenprodukte zur herstellung substituierter indazolderivate

Also Published As

Publication number Publication date
SK148298A3 (en) 2000-02-14
TW449585B (en) 2001-08-11
MA24158A1 (fr) 1997-12-31
AP1146A (en) 2003-02-25
NO985095L (no) 1998-12-29
KR100339935B1 (ko) 2002-07-18
AP1147A (en) 2003-02-25
AP9700975A0 (en) 1997-07-31
CN1217714A (zh) 1999-05-26
CO4650038A1 (es) 1998-09-03
HRP970227B1 (en) 2002-06-30
HUP9902459A3 (en) 2001-10-29
TR199802202T2 (xx) 1999-02-22
IS4871A (is) 1998-10-16
BG102946A (en) 1999-11-30
ATE292626T1 (de) 2005-04-15
PE64598A1 (es) 1998-10-26
HRP970227A2 (en) 2000-12-31
IL126547A (en) 2003-03-12
JP3148254B2 (ja) 2001-03-19
CA2252982A1 (en) 1997-11-13
DZ2217A1 (fr) 2002-12-03
BG64211B1 (bg) 2004-05-31
AP2001002304A0 (en) 2001-12-31
CN1422849A (zh) 2003-06-11
CZ349298A3 (cs) 1999-09-15
ZA973804B (en) 1998-11-02
HK1019443A1 (en) 2000-02-11
WO1997042174A1 (en) 1997-11-13
AR006906A1 (es) 1999-09-29
CN1112359C (zh) 2003-06-25
EA199800882A1 (ru) 1999-06-24
GT199700043A (es) 1998-10-02
AU1937397A (en) 1997-11-26
ES2238079T3 (es) 2005-08-16
OA10904A (en) 2001-10-11
CA2252982C (en) 2002-10-08
EP0912521A1 (de) 1999-05-06
HUP9902459A2 (hu) 1999-11-29
US6211222B1 (en) 2001-04-03
PL329836A1 (en) 1999-04-12
JPH11508284A (ja) 1999-07-21
US6127398A (en) 2000-10-03
AP2001002294A0 (en) 2001-12-31
NO312959B1 (no) 2002-07-22
DE69732966T2 (de) 2005-09-08
KR20000010751A (ko) 2000-02-25
ID16856A (id) 1997-11-13
NO985095D0 (no) 1998-11-02
CZ292825B6 (cs) 2003-12-17
AU725576B2 (en) 2000-10-12
EP0912521B1 (de) 2005-04-06
AP0102304A0 (en) 1997-11-03
HN1997000046A (es) 1997-06-26
EA002272B1 (ru) 2002-02-28
IL126547A0 (en) 1999-08-17
BR9709051A (pt) 1999-08-03
IL152083A0 (en) 2003-05-29
TNSN97070A1 (fr) 2005-03-15
YU16397A (sh) 1999-12-27
MY132499A (en) 2007-10-31
NZ332240A (en) 2000-07-28
CA2389918A1 (en) 1997-11-13
UA65536C2 (en) 2004-04-15
UY24532A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
DE69732966D1 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) des typs iv und der produktion des tumor nekrosis faktors (tnf)
DE69723447T2 (de) Substituierte indazolderivate und ihre verwendung als inhibitoren des phosphodiesterase (pde) typs 4 und des tumor-necrosin-factors (tnf)
IL128642A0 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
AU3102697A (en) Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
DE69926154D1 (de) Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
DE69722656D1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
DE69824418D1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
ATE129497T1 (de) Bicyclische pyranderivate und ihre verwendung als 5-lipoxygenasehemmer.
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
ATE421954T1 (de) Heteroaryl-hexansäureamid-derivate, ihre herstellung und ihre verwendung als selektive inhibitoren der bindung von mip-1-alpha an seinen ccr1 rezeptor
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
DE69708629T2 (de) Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva
HK1066804A1 (en) Derivatives of indole and their use as phosphodiesterase 4 inhibitors
DE60008539D1 (de) Substituierte isochinolinderivate und ihre verwendung als anticonvulsiva
ATA281087A (de) Neue therapeutische pyrrolderivate und ihre verwendung
DE69707602D1 (de) Substituierte Vinylharnstoff-Derivate und ihre Verwendung als ACAT-Inhibitoren
ATE89820T1 (de) 4-amino-3-acylchinolin-derivate, und ihre verwendung als inhibitioren der magensekretion.
PT934307E (pt) Compostos azabicíclicos substituídos e sua utilização como inibidores da produção de tnf e da fosfodiesterase do amp cíclico

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee